Shots: The EC’s approval is based on P-III STR1VE-US and P-I START studies assessing the efficacy & safety of a one-time IV infusion of Zolgensma in symptomatic SMA Type 1 patients aged <6 mos. at dosing, with one/ two copies of the SMN2 backup gene, or two copies of the SMN2 backup gene, respectively Zolgensma […]Read More
